logo

For the Inventor, By the Inventor

Duarte, CA, United States of America

Hongzhi Li

This inventor holds 8 USPTO granted patents and 2 published patent applications. Top assignees: Beckman Research Institute, City of Hope, California Institute of Technology, City of Hope. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hongzhi Li. Retrieved from https://idiyas.com/inventor/hongzhi-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 87.5

Average Co-Inventor Count = 6.3

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:

goldMedal7 out of 692 
 
Beckman Research Institute, City of Hope
 patents
silverMedal4 out of 4,626 
 
California Institute of Technology
 patents
bronzeMedal1 out of 9 
 
City of Hope
 patents
where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...
8 patents (USPTO):Explore Patents
1. 12740976 - Methods and compositions for treating cancer (2026-09-22),
2. 12576082 - METTL16 inhibitors and uses thereof (2026-03-17),
3. 11858879 - PARG inhibitors and method of use thereof (2024-01-02),
4. 11780815 - DNA2 inhibitors for cancer treatment (2023-10-10),
5. 11198675 - DNA2 inhibitors for cancer treatment (2021-12-14),
6. 10562856 - DNA2 inhibitors for cancer treatment (2020-02-18),
7. 10173984 - DNA2 inhibitors for cancer treatment (2019-01-08),
8. 9932310 - DNA2 inhibitors for cancer treatment (2018-04-03),

Title: Innovations and Contributions of Inventor Hongzhi Li

Introduction

Hongzhi Li is a prominent inventor based in Duarte, California, known for his significant contributions to cancer treatment through innovative research and development. With a total of six patents to his name, he has made strides in the field of biotechnology, particularly in the area of cancer therapeutics.

Latest Patents

Among his latest patents are the development of PARG inhibitors and methods of use thereof. This invention provides compounds that inhibit poly(ADP-ribose) Glycohydrolase (PARG) in cancer cells, offering new methods for treating cancer. Another notable patent is focused on DNA2 inhibitors for cancer treatment, which discloses compositions and methods for inhibiting DNA2, further advancing the fight against cancer.

Career Highlights

Throughout his career, Hongzhi Li has worked with esteemed institutions such as City of Hope and the California Institute of Technology. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include David A. Horne and Binghui Shen, who have played significant roles in his research endeavors.

Conclusion

Hongzhi Li's innovative work and patents in cancer treatment exemplify his dedication to advancing medical science. His contributions continue to impact the field and offer hope for improved therapeutic options for cancer patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…